Promis Neurosciences Inc (PMN) Stock Price, Quote & News

Company Profile

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers for treating Alzheimer'...

Industry: Biotechnology

Sector: Healthcare

Phone: 416 847 6898

Fax: 416 847 6899

Website: www.promisneurosciences.com

Address:

1920 Yonge Street, Suite 200, Toronto, Canada

DayTrade_4Life Jan. 30 at 11:07 PM

🏆FROM THE WATCHLIST & ALERTS TODAY 30 JAN 💰Why join the Team? To get these GAINS! Several got 100% to 800% today. Super Low Rate. See Pinned Post 🔥ELPW: $1 to 15.27 (1527%) See image. Scanner Alerted at .54 cents, I Alerted at $1. 💰APRE: .84 to 1.49 (77%) 💵ORKT: 1.35 to 1.80 (33%) 💵LRHC: 5.50 to 7.22 (31%) 💵GITS: 5.20 to 6.75 (29%) $PMN: $17.20 to 21.94 (27%) $FEED: $5 to 6.09 (21%)

0 · Reply

Lara50 Jan. 30 at 9:01 PM

$PMN and that wraps the trading day. Utter Dominance From the Bears. Belt to Ass on the Bulls. Next week: under 5$ there is no support from bulls. Short Sellers will Dominate this stock on Monday.

0 · Reply

3balledMan Jan. 30 at 8:53 PM

$PMN HorseShit stock

1 · Reply

Spinaroonie Jan. 30 at 8:51 PM

$PMN up 80 percent the past month and people complaining???

0 · Reply

Lara50 Jan. 30 at 8:43 PM

$PMN GOT KNOCKED THE F OUT 🤣🤣🤣🤣🤣🤣

0 · Reply

2HeadedIceMan Jan. 30 at 8:39 PM

$PMN I say Fuck this stock!

1 · Reply

Lara50 Jan. 30 at 8:37 PM

$PMN why go up, when you can just go down right!? This stock loves the downward trend.

0 · Reply

Blueknoser Jan. 30 at 8:19 PM

$PMN wholesale shareprice considering PMN310 appears to be working, considering an existing investor just invested another 75 million on better efficacy & no ARIA; superior drug as compared to the 2 existing treatments.

0 · Reply

Cellsci Jan. 30 at 8:10 PM

$PMN love it,now we have 2years to make a great deal with the proper pharma major,without funding pressure ! Don’t think it’s going to take that long imo.

0 · Reply

Lara50 Jan. 30 at 7:38 PM

$PMN Back to 13 again. great Job Bulls. short away.

0 · Reply

ProMIS Neurosciences Announces Up to $175 Million Private Placement Financing

Dec 18, 2025, 7:30 AM EST - 6 weeks ago

ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 in Alzheimer's Disease

Dec 10, 2025, 7:30 AM EST - 7 weeks ago

ProMIS Neurosciences Announces New Peer-Reviewed Publication Highlighting Selective Targeting of Toxic Oligomers for Potential Clinical Benefit and Reduced ARIA Risk

Dec 1, 2025, 7:30 AM EST - 2 months ago

ProMIS Neurosciences Announces New Peer-Reviewed Publication Showing Plasma pTau as a Predictive Early Endpoint in Alzheimer's trials, Supporting its Ongoing Phase 1b PRECISE-AD trial with PMN310

Dec 1, 2025, 7:00 AM EST - 2 months ago

ProMIS Neurosciences to Participate in the 8th Annual Evercore Healthcare Conference

Nov 24, 2025, 8:00 AM EST - 2 months ago

ProMIS Neurosciences Announces Reverse Stock Split

Nov 12, 2025, 7:00 AM EST - 2 months ago

ProMIS Neurosciences Announces Third Quarter 2025 Financial Results & Corporate Highlights

Nov 3, 2025, 4:05 PM EST - 3 months ago

ProMIS Neurosciences to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

Oct 22, 2025, 7:30 AM EDT - 3 months ago

ProMIS Neurosciences Strengthens Board with Appointment of Slanix Paul Alex, Pharm.D., President and Portfolio Manager, Public Equity of Ally Bridge Group

Sep 3, 2025, 7:00 AM EDT - 5 months ago

ProMIS Neurosciences Receives DSMB Approval to Advance to Final Dose Escalation Cohort in Phase 1b Alzheimer's Trial of PMN310

Aug 13, 2025, 7:00 AM EDT - 6 months ago

ProMIS Neurosciences Announces Second Quarter 2025 Financial Results & Corporate Highlights

Jul 29, 2025, 8:00 AM EDT - 6 months ago

ProMIS Neurosciences to Showcase Protein-Misfolding Drug Discovery Platform & PRECISE-AD Trial Design at the 2025 Alzheimer's Association International Conference

Jul 28, 2025, 7:00 AM EDT - 6 months ago

ProMIS Neurosciences Announces Private Placement Financing

Jul 21, 2025, 8:00 AM EDT - 6 months ago

ProMIS Neurosciences Granted Fast Track Designation by U.S. FDA for PMN310 in the Treatment of Alzheimer's Disease

Jun 17, 2025, 7:00 AM EDT - 8 months ago

ProMIS Neurosciences Presents at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

May 12, 2025, 7:30 AM EDT - 9 months ago

ProMIS Neurosciences Announces First Quarter 2025 Financial Results

Mar 31, 2025, 7:00 AM EDT - 10 months ago

ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent Highlights

Mar 24, 2025, 7:00 AM EDT - 11 months ago

ProMIS Neurosciences Showcases Preclinical Data on Platform-Derived Antibody and Vaccines for Neurodegenerative Diseases at Alzheimer's Disease/Parkinson's Disease 2025 International Conference

Mar 13, 2025, 7:00 AM EDT - 11 months ago

ProMIS Neurosciences Showcases Preclinical Data on Platform Derived Vaccines for Neurodegenerative Diseases at the American Academy of Neurology 2025 Annual Meeting

Mar 11, 2025, 7:30 AM EDT - 11 months ago

ProMIS Neurosciences to Participate in the 37th Annual Roth Conference

Feb 25, 2025, 7:00 AM EST - 1 year ago

ProMIS Neurosciences Doses First Patients in Phase 1b PRECISE-AD Trial of PMN310 for Alzheimer's Disease

Jan 29, 2025, 7:30 AM EST - 1 year ago

ProMIS Neurosciences to Participate in Guggenheim Securities SMID Cap Biotech Conference

Jan 13, 2025, 10:30 AM EST - 1 year ago

ProMIS Neurosciences Issues Letter to Shareholders

Nov 14, 2024, 9:15 AM EST - 1 year ago

ProMIS Neurosciences Announces Third Quarter 2024 Financial Results and Recent Highlights

Oct 30, 2024, 8:00 AM EDT - 1 year ago

ProMIS Neurosciences Presents Positive Data from PMN310 Phase1a Clinical Trial at the 17th Clinical Trials on Alzheimer's Disease Conference

Sep 12, 2024, 7:00 AM EDT - 1 year ago

ProMIS Neurosciences to Showcase PMN310's Ability to Target Toxic Oligomers and Distinguish from Other Amyloid-Beta Oligomers in Preclinical Studies at the 4th International Conference on Cognitive & Behavioral Neurosciences

Sep 5, 2024, 7:00 AM EDT - 1 year ago

ProMIS Neurosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 1, 2024, 7:00 AM EDT - 1 year ago

ProMIS Neurosciences to Participate in BTIG Virtual Biotechnology Conference 2024

Jul 30, 2024, 8:30 AM EDT - 1 year ago

ProMIS Neurosciences Showcases Novel Vaccine Approach for Maximal Targeting of Toxic Amyloid-Beta Oligomers at the 2024 Alzheimer's Association International Conference

Jul 26, 2024, 8:35 AM EDT - 1 year ago

ProMIS Neurosciences Reports Positive Top-Line Data from its Phase 1a Alzheimer's Trial

Jul 26, 2024, 8:30 AM EDT - 1 year ago

ProMIS Neurosciences Announces Up to $122.7 Million Private Placement Financing

May 14, 2024, 4:01 PM EDT - 1 year ago

ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights

Apr 30, 2024, 7:00 AM EDT - 1 year ago

ProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies

Apr 9, 2024, 7:00 AM EDT - 1 year ago

ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS

Apr 4, 2024, 7:00 AM EDT - 1 year ago

ProMIS Neurosciences to Present in Upcoming Investor Conferences in April

Apr 1, 2024, 4:15 PM EDT - 1 year ago

ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights

Mar 11, 2024, 7:00 AM EDT - 2 years ago

ProMIS Neurosciences Strengthens Global Intellectual Property Portfolio

Feb 22, 2024, 7:00 AM EST - 2 years ago

ProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conference

Jan 22, 2024, 7:00 AM EST - 2 years ago

ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine

Jan 3, 2024, 7:00 AM EST - 2 years ago

ProMIS Neurosciences, Inc. Announces Leadership Transition

Dec 20, 2023, 7:00 AM EST - 2 years ago

ProMIS Neurosciences Announces Publication on Novel Target for ALS

Nov 20, 2023, 7:00 AM EST - 2 years ago

ProMIS Neurosciences Doses First Subjects in Phase 1a Clinical Trial of PMN310 to Treat Alzheimer's Disease

Nov 14, 2023, 4:30 PM EST - 2 years ago

ProMIS Neurosciences Announces Third Quarter 2023 Financial Results and Recent Highlights

Sep 8, 2023, 7:00 AM EDT - 2 years ago

ProMIS Neurosciences Closes $20.4 Million Private Placement Financing

Sep 6, 2023, 12:18 PM EDT - 2 years ago

ProMIS Neurosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 21, 2023, 4:12 PM EDT - 2 years ago

ProMIS Neurosciences Announces $20.4 Million Private Placement Financing

Aug 14, 2023, 5:33 PM EDT - 2 years ago

ProMIS Neurosciences Announces Second Quarter 2023 Financial Results and Recent Highlights

Jul 17, 2023, 7:00 AM EDT - 2 years ago

ProMIS Showcases Preclinical Data at the Alzheimer's Association International Conference 2023 on Computationally-Derived Antibody and Vaccine from Alzheimer's Pipeline

Jul 14, 2023, 7:45 AM EDT - 2 years ago

ProMIS Announces Completion of Continuance

Jul 10, 2023, 7:55 AM EDT - 2 years ago

ProMIS Neurosciences to Consolidate Trading on the Nasdaq Exchange

DayTrade_4Life Jan. 30 at 11:07 PM

0 · Reply

Lara50 Jan. 30 at 9:01 PM

$PMN and that wraps the trading day. Utter Dominance From the Bears. Belt to Ass on the Bulls. Next week: under 5$ there is no support from bulls. Short Sellers will Dominate this stock on Monday.

0 · Reply

3balledMan Jan. 30 at 8:53 PM

$PMN HorseShit stock

1 · Reply

Spinaroonie Jan. 30 at 8:51 PM

$PMN up 80 percent the past month and people complaining???

0 · Reply

Lara50 Jan. 30 at 8:43 PM

$PMN GOT KNOCKED THE F OUT 🤣🤣🤣🤣🤣🤣

0 · Reply

2HeadedIceMan Jan. 30 at 8:39 PM

$PMN I say Fuck this stock!

1 · Reply

Lara50 Jan. 30 at 8:37 PM

$PMN why go up, when you can just go down right!? This stock loves the downward trend.

0 · Reply

Blueknoser Jan. 30 at 8:19 PM

0 · Reply

Cellsci Jan. 30 at 8:10 PM

$PMN love it,now we have 2years to make a great deal with the proper pharma major,without funding pressure ! Don’t think it’s going to take that long imo.

0 · Reply

Lara50 Jan. 30 at 7:38 PM

$PMN Back to 13 again. great Job Bulls. short away.

0 · Reply

2HeadedIceMan Jan. 30 at 7:27 PM

$PMN seemed like it was trying to be an afternoon runner but then decided to kick itself in the nuts

0 · Reply

Lara50 Jan. 30 at 7:27 PM

$PMN very greedy short sellers

0 · Reply

MisterJST Jan. 30 at 7:07 PM

$PMN damn spready

1 · Reply

WadehN21 Jan. 30 at 7:01 PM

$PMN i stick by this

0 · Reply

Blueknoser Jan. 30 at 6:48 PM

$PMN

0 · Reply

2HeadedIceMan Jan. 30 at 6:40 PM

$PMN and the almost 3% difference in the ask and bid price sucks

0 · Reply

2HeadedIceMan Jan. 30 at 6:37 PM

$PMN these are all stupidly low candle volumes on the 1 minute candles. Me and 3 other bagholders could easily drive up the price by selling a few shares to each other back and forth in between the ask an bid price then after it gains some false momentum dump our bags and head to the nearest Chili’s for shots of tequila

0 · Reply

MoxeysPal Jan. 30 at 6:36 PM

$RR ppl, rr buys robotics from China then rebrands them. Look at the bod. Don't get scammed. $PMN $SAPMF $SAPMY for profits

3 · Reply

DARKP00L Jan. 30 at 6:33 PM

$ALLO If you’re not in our community sever, you’re missing out on these alerts! [Link in Bio] We $APRE Stay $ASBP Lit $PMN #darkpoolai #daytrader #nyse

0 · Reply

Catalina1965 Jan. 30 at 6:15 PM

$PMN Hit 15.39 and fell completely apart.

0 · Reply

Catalina1965 Jan. 30 at 6:14 PM

$PMN What was that?

0 · Reply

Misterx69 Jan. 30 at 5:41 PM

$PMN 19.84$ today hit

0 · Reply

Market Cap	26.00M
Revenue (ttm)	0.00
Net Income (ttm)	2.78M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	7,915,700
Avg Vol	30,173
Day's Range	N/A - N/A
Shares Out	2.15M
Stochastic %K	91%
Beta	-0.10
Analysts	Strong Sell
Price Target	$26.50